Abstract
Limited data exist on the economic burden of medication overuse among patients with migraine. This study aims to estimate a) annual all-cause healthcare resource utilization (HRU) and costs and b) annual migraine-related HRU and costs associated with drug-induced headache (DIH) and with potential acute medication overuse (AMO) among commercially insured migraine patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
